This HTML5 document contains 32 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n9http://edrn.nci.nih.gov/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n12https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
freebasehttp://rdf.freebase.com/ns/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Mesomark_assay
rdfs:label
Mesomark assay
rdfs:comment
The Mesomark Assay is an in vitro test to monitor and possibly diagnose pleural mesothelioma and peritoneal mesothelioma. Developed by Fujirebio Diagnostics and approved in late January 2007 by the U.S. Food and Drug Administration (FDA), it works by measuring levels of soluble mesothelin-related proteins (SMRPs) released by diseased mesothelioma cells. The SMRP levels correlate directly with tumor volume thus permitting less invasive monitoring and improved assessment of treatment response.
dbp:name
Mesomark assay
dcterms:subject
dbc:Cancer_screening
dbo:wikiPageID
10018781
dbo:wikiPageRevisionID
984456525
dbo:wikiPageWikiLink
dbr:Fujirebio dbr:Peritoneal_mesothelioma dbc:Cancer_screening dbr:Pleural dbr:Mesothelioma dbr:Food_and_Drug_Administration_(United_States) dbr:EDRN dbr:Mesothelin dbr:In_vitro
dbo:wikiPageExternalLink
n9:
owl:sameAs
freebase:m.02pzzq8 n12:4rdCr wikidata:Q6821530
dbp:wikiPageUsesTemplate
dbt:Infobox_diagnostic dbt:Med-sign-stub dbt:Reflist dbt:Oncology-stub
dbp:purpose
diagnose of Pleural Mesothelioma and Peritoneal Mesothelioma
dbo:abstract
The Mesomark Assay is an in vitro test to monitor and possibly diagnose pleural mesothelioma and peritoneal mesothelioma. Developed by Fujirebio Diagnostics and approved in late January 2007 by the U.S. Food and Drug Administration (FDA), it works by measuring levels of soluble mesothelin-related proteins (SMRPs) released by diseased mesothelioma cells. The SMRP levels correlate directly with tumor volume thus permitting less invasive monitoring and improved assessment of treatment response. The MESOMARK assay is the most well-known and the world's first blood serum-based test for diagnosing mesothelioma. However, as certain types of tumors (such as sarcomatoid mesothelioma) do not release SMRP, the FDA recommends that doctors use the MESOMARK assay in conjunction with other tests to ensure an accurate mesothelioma diagnosis. In the future, the test may be used as an early detection measure as evidenced by recently sponsored tests by the Early Detection Research Network of the National Cancer Institute [1].
prov:wasDerivedFrom
wikipedia-en:Mesomark_assay?oldid=984456525&ns=0
dbo:wikiPageLength
2636
foaf:isPrimaryTopicOf
wikipedia-en:Mesomark_assay
Subject Item
dbr:Mesomark
dbo:wikiPageWikiLink
dbr:Mesomark_assay
dbo:wikiPageRedirects
dbr:Mesomark_assay
Subject Item
dbr:Mesothelioma
dbo:wikiPageWikiLink
dbr:Mesomark_assay
Subject Item
wikipedia-en:Mesomark_assay
foaf:primaryTopic
dbr:Mesomark_assay